Assessing new diagnostic products drives US regulators to study discrepancies
This article was originally published in Clinica
Executive Summary
The FDA's Division of Clinical Laboratory Devices is searching for a solution to a perennial headache for in vitro diagnostic reviewers - how to assess new products against a flawed gold standard.